Cerity Partners
KURA icon

Cerity Partners’s Kura Oncology KURA Stock Holding History

Cerity Partners’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
124,082
+23,060
+23% +$218K ﹤0.01% 1802
2026
Q1 		$821K Sell
101,022
-33,289
-25% -$286K ﹤0.01% 1969
2025
Q4 		$1.4M Buy
134,311
+40,467
+43% +$425K ﹤0.01% 1541
2025
Q3 		$831K Buy
93,844
+38,174
+69% +$272K ﹤0.01% 1690
2025
Q2 		$321K Buy
55,670
+23,814
+75% +$146K ﹤0.01% 2120
2025
Q1 		$210K Buy
+31,856
New +$248K ﹤0.01% 2194

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Cerity Partners's KURA Position: Q2 2026 in Review

Cerity Partners increased its Kura Oncology (KURA) stake by 23% in Q2 2026, buying an estimated $218K and bringing the position to 124,082 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

Cerity Partners first reported a position in KURA in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.4M in Q4 2025. 205 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Cerity Partners held 124,082 shares of Kura Oncology worth $1.36M as of Q2 2026.
  • Cerity Partners bought 23,060 Kura Oncology shares in Q2 2026, an estimated $218K.
  • Kura Oncology made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1802 holding.
  • Cerity Partners first reported a position in Kura Oncology in Q1 2025 and has held it in 6 quarters since.
  • Cerity Partners's Kura Oncology position peaked at $1.4M in Q4 2025.
  • 205 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.